Report: Price hikes are still driving pharma's earnings growth. Who's most at risk?

Fierce Pharma ------- Defying pressure from politicians and the public, pharma largely continued its price-hiking ways in 2016, with the corresponding sales windfall equal to 100% of the industry’s EPS growth for the year. That’s one conclusion in a new report from Credit Suisse, which found that net price hikes in the U.S. last year created $8.7 billion in net income for top pharma companies, equivalent to all of the sector’s earnings growth. That's an industrywide stat, so it doesn't hold true for every individual pharma company. But for Biogen, Eli Lilly, AbbVie, Allergan, Merck & Co., Pfizer and Amgen, net price hikes created additional sales equal to all of their net income growth for the year, according to the analysts' calculations. To learn more click on the picture below to read the article.